ArticleScientific reports2025
The high value utilization characteristics of coal gangue powder with emulsified asphalt mastic through rheological and viscoelastic damage theory.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Physicochemical synergy and rheological performance of asphalt mastics modified with industrial waste precipitated calcium carbonate.Scientific reports · 2026Article
- Sustainable Utilization of Coal Gangue in Asphalt Pavement: A Review on Design, Mechanism, and Performance.Materials (Basel, Switzerland) · 2025Review
- Mine Tailings as a Sustainable Filler for Asphalt Binder-Mastics: A Review.Materials (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
In order to solve the problems of rutting and early fatigue cracks in emulsified asphalt cold recycled pavement, and the shortage of natural stone resources and new environmental hazards caused by the use of traditional limestone powder filler. In this study, coal gangue powder was added to prepare Emulsified Asphalt Mastic (EAM) to improve the rheological properties and fatigue performance. A series of tests, including frequency scanning, temperature scanning, Multiple Stress Creep Recovery (MSCR), Linear Amplitude Scanning (LAS), and Fourier Transform Infrared spectroscopy (FTIR) were conducted. Through rheology theory, viscoelastic damage theory, the impact of three fillers: Coal Gangue Powder (CGP), Limestone Powder (LP) and Portland Cement (PC), as well as four kinds of Powder-Binder ratios (P/B) (0.6, 0.9, 1.2, 1.5) on the high temperature rheology and medium temperature fatigue performance of EAM was analyzed. The findings reveal that the filler content has a great influence on the proportion of viscoelastic components of EAM in the low frequency domain. The complex shear modulus (G*) and phase angle (δ) of EAM were suitable for Christensen-Anderson-Marasteanu model (CAM) model in the wide frequency domain. Increasing the filler content and Rotating Thin Film Oven Test (RTFOT) aging can improve the high-temperature stability and stress sensitivity of EAM, but it reduced its fatigue resistance. The high temperature performance of EAM containing PC and CGP exhibit superior high-temperature performance compared to LP fillers. Conversely, LP mastic demonstrate superior anti-fatigue performance under actual strain levels in both thin and thick asphalt pavement layers, surpassing the performance of PC mastic and CGP mastic. Therefore, coal gangue powder can be used as a new type of green filler to replace limestone powder. An appropriate amount of incorporation can improve the high temperature stability of the mortar and does not have a huge impact on the fatigue performance. The most suitable range of P/B is identified as 0.6-1.0 when utilizing LP as the filler, 1.2-1.5 when utilizing PC or CGP as the filler.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.